Skip to main content

DESCIFRANDO EL ROL DE LAS MUTACIONES EN EL COMPLEJO DE LAS COHESINAS Y LA ESTRUCTURA 3D DEL GENOMA EN LEUCEMIA MIELOIDE

PID2020-117950RA-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Down syndrome and leukemia, from basic mechanisms to clinical advances

  • Baruchel, André
  • Bourquin, Jean Pierre
  • Crispino, John
  • Cuartero, Sergi|||0000-0002-9338-583X
  • Hasle, Henrik
  • Hitzler, Johann
  • Klusmann, Jan Henning
  • Izraeli, Shai
  • Lane, Andrew A.
  • Malinge, Sebastien
  • Rabin, Karen R.
  • Roberts, Irene|||0000-0002-6094-6397
  • Ryeom, Sandra
  • Tasian, Sarah K.
  • Wagenblast, Elvin
Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the Jérôme Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.